AI’s Impact on Elections: New Policy Paper Highlights Urgent Global Challenge
24.1.2025 14:01:00 EET | Business Wire | Press release
Artificial intelligence (AI) is transforming political campaigns worldwide, creating unprecedented opportunities while amplifying risks for democratic processes. According to the newly launched policy paper, The Pervasive Influence of AI on Global Political Campaigns 2024, AI-driven techniques, such as generative AI (genAI), have revolutionized voter engagement through personalized messaging. However, genAI has also emerged as a double-edged sword: while enabling effective campaigning, it has been a significant source of disinformation, eroding trust in democratic institutions.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250122148789/en/
Future Shift Labs Co-founder Sagar Vishnoi addresses IPE25 in Cape Town (Photo: Business Wire)
For instance, the United States, classified as “severely polarized” and ranked 3rd among 28 countries for polarization, illustrates how AI-generated propaganda exacerbates societal divisions. Further, the U.S. ranks 1st in distrust of social media, exposing vulnerabilities to AI-driven disinformation campaigns. Russia’s Foreign Influence and Malign Interference (FIMI) activities have prominently leveraged AI tools to spread targeted propaganda. Generative AI platforms like "Doppelganger" have repeatedly been used to sow disinformation and undermine public trust globally. The study underscores the urgent need for governments to regulate AI in elections to prevent future misuse and safeguard democratic integrity.
The policy paper, authored by Alisha Butala, Dr. Christopher Nehring, and Mateusz Łabuz, was developed by Future Shift Labs, a global think tank exploring AI and governance. Officially unveiled on the 23rd of January at the IPE Campaign Expo 2025 in Cape Town, South Africa, the paper provides actionable insights and global case studies. It emphasizes the importance of clear regulations, ethical standards, and investment in public education to combat AI-enabled electoral interference.
Nitin Narang, Founder of Future Shift labs who played a pivotal role in bringing this project to fruition, remarked: "At its core, this research is about people - voters, citizens, and communities. Our team's work is driven by a shared commitment to understanding how AI is reshaping our democratic landscape. By shedding light on these critical issues, we hope to contribute to a more informed, inclusive, and resilient global conversation."
Dr. Israel Govender, a thought leader in technology governance, added: “As we reflect on AI's rapid evolution, our choices today will shape the future of democracy. This research provides a critical perspective on the impact of technology on our values and institutions, serving as a valuable resource for responsible innovation.”
Sagar Vishnoi, Co-founder of Future Shift Labs, and Glen Mpani, organizer of IPE 2025, were present at the launch, reinforcing the think tank's commitment to fostering global discussions on AI governance, transparency, and accountability. Vishnoi notes "Blockchain technology will become the base for other applications in political campaigns, blending seamlessly into the ecosystem, much like AI's current role."
Future Shift Labs is an emerging global think tank dedicated to advancing AI policies and integrating digital statecraft with cutting-edge technologies. The IPE Campaign Expo 2025, renowned for showcasing political innovations, and Kairos Communications, as the principal partner, provided the perfect platform for this milestone launch.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250122148789/en/
Contacts
Aastha Naresh Kohli
Head of Communications
Future Shift Labs
91675 32608
Aastha@futureshiftlabs.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com

Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Plasma One Launches to Herald a New Era of Stablecoin Banking19.6.2026 15:29:00 EEST | Press release
Plasma has today announced the launch of Plasma One, its flagship financial product designed to make digital dollars usable for everyday spending, sending and earning. Plasma One is designed to make stablecoins feel like money, only better - more accessible, reliable and efficient. For years, stablecoin adoption has been held back by a fragmented system and poor user experience. We have seen wallets in one place, exchanges in another, and costly off-ramps standing between digital dollars and daily life. Plasma One brings that experience together in a single app, giving users a simple way to spend, send and earn with stablecoins from one account with zero fees. Headquartered in London, the city that gave rise to Revolut, Wise and Monzo, Plasma is making a bigger bet, that the next generation of consumer banking will be built on stablecoin rails, not legacy banking infrastructure. Underneath Plasma One is the Plasma Network, Plasma’s own blockchain, purpose-built to move stablecoins inst
IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist19.6.2026 10:00:00 EEST | Press release
IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a merger with Real Asset Acquisition Corp. (Nasdaq: RAAQ). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260619693929/en/ From left to right: Dr. Inés de Vega, Chief Scientist, and Dr. Craig Ciesla, Chief Technology Officer. Ciesla, an experienced deep tech executive with more than 25 years delivering products across multiple industries from startups to Fortune 500 companies, will advance IQM's technology strategy and drive its implementation into systems and products. De Vega, meanwhile, will be responsible for ensuring scientific feasibility and system-level
Teijin Receives Approval for Additional Indications of XEOMIN ® for Cervical Dystonia and Blepharospasm in Japan19.6.2026 10:00:00 EEST | Press release
Teijin Pharma Limited, the core company of the Teijin Group’s healthcare business, and Merz Therapeutics GmbH, a leading player in neurology-focused specialty pharma, jointly announced today that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved the additional indications for XEOMIN® (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm. This approval represents the fourth and fifth indications for XEOMIN® authorized in Japan, alongside its existing approvals for the treatment of upper limb spasticity, lower limb spasticity and chronic sialorrhea. Cervical dystonia is a focal dystonia characterized by involuntary contractions of the neck muscles, resulting in abnormal or repetitive movements and postures.1 Blepharospasm is also a focal dystonia, characterized by excessive involuntary contractions of the muscles surrounding the eye.2 Both conditions significantly impact patients’ quality of life. The approval by MHLW is based on Phase III clinic
Incyte Japan Announces Approval of Minjuvi ® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)19.6.2026 09:00:00 EEST | Press release
Incyte Biosciences Japan G.K. today announced that Japan’s Ministry of Health, Labour and Welfare (MHLW) has approved Minjuvi® (tafasitamab) in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). “This approval provides a new option for patients in Japan living with relapsed or refractory DLBCL, an aggressive disease with historically limited treatment options,” said Yasuyuki Ishida, General Manager, Incyte Biosciences Japan. “We are committed to helping address critical unmet needs for patients and their families affected by this challenging cancer.” DLBCL is the most common subtype of non-Hodgkin lymphoma and is an aggressive malignancy of B lymphocytes. While many patients respond to initial therapy, outcomes remain poor for those with relapsed or refractory disease, particularly for patients who are not eligible for autologous stem cell transplant.1 The approval is based on results from the MOR208C203 Trial: L
Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training18.6.2026 20:07:00 EEST | Press release
Amazfit, a leading global smart wearable brand owned by Zepp Health (NYSE: ZEPP), today announced Helio Strap Pro, a body-worn training system designed to help HYROX and hybrid athletes better understand how their bodies perform under load. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260618031434/en/ Amazfit Introduces Helio Strap Pro, Bringing Body-Worn Movement Intelligence to HYROX and Hybrid Training Building on the screen-free Helio Strap, Helio Strap Pro adds a dedicated waist-mounted motion sensor that captures core-body movement and stability during training. Combined with upper-arm heart-rate sensing and compatible Amazfit smartwatches, the system provides a more complete picture of cardio effort, movement quality and muscle load than wrist-based tracking alone. Helio Strap Pro represents the next evolution of Amazfit's Hybrid Training System, extending performance tracking beyond heart rate to help athletes bett
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom